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Abstract 
The choice of the tumor antigen preparation u s e d   f o r   dendritic cell (DC) loading is important 
for optimizing DC vaccines.  In the present study, we compared DCs pulsed with hepato-
cellular carcinoma (HCC) t o t a l   R N A   o r   cell lysates for their capacity to activate T cells.  We 
showed here that HCC total RNA pulsed-DCs induced effector T lymphocyte responses 
which showed higher killing ability to HCC cell lines,   a s   w e l l   a s   h i g h e r   frequency of IFN-γ 
p r o d u c i n g   o f   C D 4 +   a n d   C D 8 +   T   c e l l s   w h e n   c o m p a r e d   w i t h   l y s a t e   p u l s e d -D C s .     B o t h   o f   R N A  
a n d   l y s a t e   l o a d i n g   d i d   n o t   influence the changes of mature DC phenotype and the capacity of 
inducing T cell proliferation.  However, HCC lysate loading significantly inhibited the pro-
duction  of  inflammatory  cytokines  IL-12p70,  IFN-γ  and  enhanced  the  secretion  of  an-
ti-inflammatory cytokines IL-10 of mature DCs.  Our results indicated that DCs loaded with 
H C C   R N A   a r e   s u p e r i o r   t o   t h a t   l o a d e d   w i t h   l y s a t e   i n   priming anti-HCC CTL response, 
suggesting that total RNA may be a better choice for DCs-based HCC immunotherapy. 
Key words: Dendrtic cells, tumor total RNA, tumor lysate, hepatocellular carcinoma, cytotoxic T 
cells 
Introduction 
Hepatocellular carcinoma (HCC) is one  of  the 
most  common  cancers  t h a t   t y p i c a l l y   h a s   p o o r   p r o g-
nosis.  It is the third leading cause of cancer deaths 
worldwide, especially in Asia (1-3).  Traditional the-
rapeutic modalities such as hepatic resection did not 
significantly increase the 5-year survival rate.    There-
fore,  it  is  urgently  required  to  develop  novel  treat-
ment  strategies  for  HCC.    Dendritic  cells  (DC)  are 
highly specialized antigen-presenting cells (APC) that 
control  a  spectrum  of  innate and adaptive  immune 
responses, and could effectively induce cytotoxic  T 
lymphocyte (CTL) response against cancer (4, 5).  The 
objective  regressions  after  DC-based  treatments  are 
observed in some patients, even in those with metas-
tatic disease (6, 7).    Recently, increasing reports dem-
onstrated  that  HCC  antigen-loaded   D C   c o u l d   p r o-
mote the priming of specific CTL responses, including 
in vivo and in vitro m o d e l   ( 8 ,   9 ) .     I n   c l i n i c a l   t r i a l ,   s o m e  
o f   H C C   p a t i e n t s   s h o w e d   s t a b l e   d i s e a s e   a f t e r   v a c c i-
nated  with  HCC  lysate-pulsed  DCs  (10-12).    These 
studies  clearly  demonstrated  that  DC-based  immu-
notherapy  could  be a promising approach  for  HCC 
treatment.  
A critical issue in optimizing DC vaccines is the 
choice  of  tumor  antigen  for  DC  loading.    Loading 
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o f   D C s   w i t h   p e p t i d e s   d e r i ved f r o m   d e f i n e d   a n t i g e n s   i s  
the  most  commonly  used strategy (13).    The limita-
tions of this method are that the tumor antigen must 
have been identified, and only a restricted repertoire 
of T-cell clones could be induced, thereby limiting the 
ability of the immune system to control tumor antigen 
variation (5).    An  alternative  strategy  is  loading DC 
with total tumor antigen such as tumor lysate, which 
could  generate  a  diverse  immune  response  that  in-
v o l v e s   m a n y   C D 4 +   T -cell  and  CTL  clones  against 
tumor  antigens,  including  both  identified  and  un-
identified antigens.    Tumor cell lysate has been widely 
used  as  total  antigen  for  DC-b a s e d   c a n c e r   i m m u n o-
therapy, including HCC (11, 12).  However,  several 
studies  recently  reported  that  tumor  lysate  would 
impair the functio n   o f   D C s   a n d   r e s u l t   i n   l i m i t e d   i m-
mune responses, indicated the potential disadvantage 
of tumor lysate (14-16).  Another commonly used total 
antigen is tumor-derived RNA, which is an attractive 
method  because  its isolation  and  use  in  clinical  set-
tings  is  m o r e   s t r a i g h t f o r w a r d   t h a n   t h e   u s e   o f   e x-
ogenously  provided  peptides  and  proteins  (17).  
L o a d i n g   D C   w i t h   R N A   h a s   b e e n   t u r n e d   o u t   t o   e f f i-
ciently stimulate robust CTL responses and antitumor 
immunity  in  human,  including  in  vitro  study  and 
clinical trial (18-24), suggesting that RNA-loaded DC 
m i g h t   b e   a   p r o m i s e   strategy for  cancer  immunothe-
r a p y .     S o   f a r ,   t h e r e   a r e   f e w  studies on the relative ef-
ficacy of l y s a t e   o r   R N A  loading  methods  to  be per-
formed in HCC.   
T h u s ,   i n   t h e   p r e s e n t   s t u d y   w e   c o m p a r e d   D C   e i-
ther loaded with tumor lysates or RNA from the same 
H C C   c e l l   l i n e   f o r   t h e i r   c a p a c i t y   t o   s t i m u l a t e   specific 
anti-HCC immune responses.  In a  separate  in vitro 
model  of  whole  HCC  antigen  loading,  our  studies 
showed  that  pulsing  DCs  with  HCC  total  RNA  in-
duced  a  higher  frequency  of  activated  CTLs  and 
T-helper  cells,  as  well  as  stronger  tumor  cell  lysis 
compared  with  lysate.    These  results  provide  new 
information for optimization of DCs-based immuno-
therapy in HCC.   
Material and Methods 
Cell Lines and Culture 
Different  human  HCC  cell  lines,  Hep-G2, 
Hep-3 B ,   w e r e   o b t a i n e d   f r o m   t h e   A m e r i c a n   T y p e  
Culture Collection (ATCC).  Huh-7, SMMC-7721 cell 
lines  were  obtained  from  the  Committee  of  Type 
Culture  Collection  of  Chinese  Academy  of  Sciences 
(Shanghai, China).    Cells were grown in RPMI  1640 
supplemented with 10% (v/v) FBS (fetal bovine se-
rum)  and  antibiotics  (50  μg/ml  each  of  penicillin, 
streptomycin and gentamicin) at 37 °C in a humidified 
5% CO2 atmosphere.   
Culture of Human DCs 
PBMC  were  isolated  from  peripheral  blood  of 
healthy donors by Ficoll-Hypaque gradient centrifu-
gation.  And then, monocytes were allowed to adhere 
in six-w e l l   c u l t u r e   p l a t e s   f o r   1   h o u r   at 3 7 º C .     N o n a d-
herent cells were removed and cultured in 20 U/ml 
IL-2  medium  for  further  use.    Adherent  cells  were 
cultured in AIM-V complete medium supplemented 
with  1,000  U/ml  GM-CSF  and  40 0   U / m l   I L -4  (Bio-
So u r c e ,   U S A ) .     H a l f   o f   t h e   o l d   m e d i u m   w a s   r e p l a c e d  
e v e r y   2   d a y s   w i t h   f r e s h   m e d i u m .     A f t e r   c u l t u r e   f o r   6  
days, immature dendritic cells (iDCs) were generated.   
Tumor cell RNA or Lysates Loading of Cultured 
DCs 
Total RNA was extracted from HCC cell lines 
using  Trizol reagent (Invitrogen,  USA)  according  to 
t h e   m a n u f a c t u r e r ’ s   i n s t r u c t i o n s .     T u m o r   c e l l   l y s a t e s  
were generated by four rapid freeze-thaw cycles as 
described (25).  Both RNA and protein loading of DCs 
w a s   p e r f o r m e d   b y   s i m p l e   c o i n c u b a t i o n   o f   D C s   w i t h-
out any transfection reagent. In brief, immature DCs 
generated  on  day  6  w e r e   w a s h e d   t w i c e   i n   P B S ,  
c o u n t e d ,   a n d   r e s u s p e n d e d   i n   A I M -V  medium  sup-
plemented with GM-CSF and IL-4.  Then tumor cells 
R N A   o r   l y s a t e s   w e r e   a d d e d   ( 2 0   μ g   R N A   o r   1 0 0   μ g  
lysates/5×105  DCs  in 1 ml medium)  and  incubated 
w i t h   D C s   f o r   3   h o u r   i n   a   h u m i d i f i e d   i n c u b a t o r   a t  
37°C/5%  CO2.    After  3  hours,  antigen-loaded  DCs 
w e r e   t r e a t e d   w i t h   0 . 1   K E / m l   ( 1 0   μg/ml)  OK432 
(Shandong Lukang Pharmaceutical Co., China) for 48 
hour. 
In Vitro Generation of CTLs and Cytotoxicity 
Assays 
Antigen loading-DCs were cocultured with au-
tologeous nonadherent PBMCs from the same healthy 
donor at a ratio of 1:10 in AIM-V medium containing 
IL-2 (25 units/ml) in 24 well plates.    H a l f   o f   t h e   o l d  
medium was replaced every 2 days with fresh me-
dium.    After 5 d a y s   o f   c o c u l t u r e ,   t h e   c e l l s   w e r e   u s e d  
for  cytotoxicity  assays  using  the  lactat  dehydroge-
nase-release assay (CytoTox 96;  Promega,  USA)  ac-
cording to the protocol.   
Phenotypic Analysis of DC by Flow Cytometry 
DCs o r   T   c e l l s   were re-suspended  at  2.5  ×  105 
cells in 100 μl of PBS and incubated for 30 min at 4ºC 
with  different  fluorescein  isothiocyanate  (FITC)- 
conjugated  monoclone  antibodies  (mAbs)  or  appro-
priate  isotype  controls.    After  three  washes  in  cold 
phosphate-buffered saline (PBS) supplemented with Int. J. Biol. Sci. 2010, 6 
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0 . 5 %   o f   b o v i n e   s e r u m   a l b u m i n   ( B S A ) ,   c e l l s   w e r e   f i x e d  
with  2%   p a r a f o r m a l d e h y d e   i n   P B S .     The  following 
mAbs  were  used:  FITC-anti-CD80,  FITC-anti-CD83, 
FITC-anti-CD86,  FITC-anti-HLA-DR  (BD Biosciences, 
USA).  C e l l s   w e r e   c o l l e c t e d   a n d   a n a l y z e d   u s i n g   a   C y-
tomicsTM FC500 Flow Cytometry (Beckman Coulter).  
Data analysis was performed by CXP Analysis soft-
ware (Beckman Coulter).   
Mixed Lymphocyte Reaction (MLR) 
For proliferation assays, non-adherent cells col-
lected from freshly isolated PBMC were resuspended 
i n   P B S   ( 1   x   1 0 7  cells/ml)  containing  carboxyfluo-
rescein diacetate succinimidyl ester (CFSE, Molecular 
Probes) at a final concentration of 1 µM, incubated at 
37°C for 10 min, and washed three times.  And then 
the  labeled  cells  were  coincubated  with  anti-
gen-loading DC pretreated with OK-432 for 5 days at 
1:10 ratios on a 48-well plate in AIM-V medium.  Cells 
were harvested and analyzed by FACS.  Data analysis 
was performed using CXP  Analysis  software  (Beck-
man Coulter).  
Analysis of Cytokines 
Cytokines TNF-α,  IL-12p70,  IFN-γ,  IP-10,  IL-10 
and TGF-β in the supernatants of differently treated 
DCs  cultures  were  m e a s u r e d   b y   E L I S A   k i t s   ( Bio-
Source  Systems)  according  to  the  manufacturer’s 
protocols. 
Flow Cytometric Analysis of Intracellular Cyto-
kine Expression 
T o   d e t e r m i n e   t h e   s t i m u l a t i o n   o f   T   c e l l s   b y   HCC 
antigen-loading  DCs, IFN-γ and IL-4 expression was 
assessed by intracellular staining.    Briefly, T cells were 
collected and incubated at 37°C for 6 h in AIM-V me-
dium containing 1 μg/ml anti-CD3 mAb and 1 μg/ml 
anti-CD28  mAb (BD Biosciences, USA).  Brefeldin A, 
10 ng/ ml, was added for the final 5 h of incubation to 
block  cytokine  secretion.   The cells were harvested, 
washed and stained w i t h   P E -conjugated anti-C D 4   a n d  
FITC-conjugated  anti-C D 8   m A b   f o r   3 0   m i n   o n   i c e .  
Then the cells were fixed with 2% paraformaldehyde 
i n   p h o s p h a t e   b u f f e r e d   s a l i n e   ( P B S )   f o r   1 5   m i n   a t   r o o m  
temperature and permeabilized with PBS/0.5% sapo-
nin (Sigma, St Louis, MO) for another 10 min at room 
temperature.  Finally, cells were further labeled with 
APC-conjugated  anti-IFN-γ   o r   a n t i -IL-4  mAb  and 
analyzed by flow cytometer. 
Statistical Analysis 
D a t a   w e r e   c o m p a r e d   u s i n g   t h e   Student’s t test, 
and differences of p<0.05 w e r e   c o n s i d e r e d   t o   b e   s i g-
nificant.  Each experiment was repeated at least three 
times. 
Results 
Cytolytic Activity of the T cells Against HCC Cell 
Lines in vitro 
First,  we  detected  cytotoxic  activity  o f   T   c e l l s  
ind u c e d   b y   D C   l o a d e d   w i t h   R N A   o r   l y s a t e   f r o m   t h e  
H C C   c e l l   l i n e .     A s   d e m o n s t r a t e d   i n   F i g .   1 ,   b o t h   H C C  
RNA and lysate-pulsed D C s   w e r e   c a p a b l e   o f   s t i m u-
lating CTLs that recognized and lysed HCC cell lines.  
H o w e v e r ,   l o a d i n g   D C   w i t h   R N A   c o u l d   i n d u c e   t h e  
better  lytic  activity  than  lysate  (the  percentages  of 
cytotoxicity were between approximately 10% to 23% 
f o r   R N A   l o a d i n g   g r o u p   v s   4 %   t o   9 %   f o r   l y s a t e -pulsed 
group at an effector : target ratio of 30 : 1, p<0.05).  We 
used four different HCC cell lines for detection,  and 
t h e   s a m e   t r e n d   w a s   o b s e r v e d   ( F i g .   1 ) ,   i n d i c a t e d   t h a t  
loading DC with RNA might stimulate higher cyto-
lytic activity of the T cells against HCC. 
Cytokine Production of CD4+ and CD8+ T Cells 
The  intracellular  staining  for  IFN-γ  and  IL-4 
production  were  carried  out  to  further  assess  the 
function of the T cells generated from co-culture with 
H C C   R N A   o r   l y s a t e   p u l s ed-DCs.    From the Fig. 2, we 
found  that  RNA  pulsed-DCs  induced  significant 
higher numbers of IFN-γ+CD4+ and IFN-γ+CD8+  T 
cells compared  to lysate pulsed-DCs.    Low  levels  of 
IL-4   p r o d u c i n g   w e r e   d e t e c t e d   i n   T   c e l l s   s t i m u l a t e d   b y  
both type antigen pulsed-D C s   ( d a t a   n o t   s h o w ) .     T h e s e  
r e s u l t s   i n d i c a t e   t h a t   H C C   R N A   p u l s e d -DCs  activate 
T h 1   a n d   C T L   f u n c t i o n a l   T   c e l l s   m o r e   efficiently than 
HCC lysate pulsed-DCs. 
Effect of HCC Total RNA or Lysate Pulsing on 
DCs Phenotype Changes and Cytokines Produc-
tion 
Next,  DCs immunophenotype  changes and  cy-
tokine production were detected by flow cytometre 
and ELISA to analyze the effects of HCC total RNA or 
lysate  o n   D C s   m a t u r a t i o n .     A s   s h o w n   i n   F i g .   3 ,   u n-
treated DCs exhibited low-level expression  of  costi-
mulatory  molecules  CD80, CD86  a s   w e l l   a s   t h e   m a-
turation marker CD83, HLA-DR.    OK-432 stimulation 
significantly  increased  CD80,  CD83,  CD86  and 
HLA-D R   e x p r e s s i o n .     B o t h   o f   H C C   t o t a l   R N A   a n d  
l y s a t e   p u l s i n g   e n h a n c e d   C D 8 0   e x p r e s s i o n   b u t   d i d   n o t  
significantly alter CD83, CD86 and HLA-DR  expres-
sion of mature DCs.  These results indicated that HCC 
t o t a l   R N A   o r   l y s a t e   p u l s i n g   d i d   n o t   inhibit costimu-
latory molecules and maturation marker expression of 
mature DCs.   
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Figure 1. T u m o r   c e l l   k i l l i n g   b y   T cells stimulated with tumor antigen-pulsed DCs.    Autologeous nonadherent PBMCs were 
c o c u l t u r e d   w i t h   D C s   p u l s e d   w i t h   H C C   t o t a l   R N A   o r   l y s a t e .     A f t e r   5  days of incubation, cytotoxic activity of T cells against 
Hep-G2, Hep-3B, Huh-7 and SMMC-7721 was evaluated using a LDH release assay at different E:T ratios.  *p<0.05. Int. J. Biol. Sci. 2010, 6 
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Figure 2. Intracellular IFN-γ production of CD4+ and CD8+ T-cells stimulated with DC pulsed with HCC total RNA or 
lysate.    Autologeous nonadherent PBMCs w e r e   c o c u l t u r e d   w i t h   R N A -DCs or lysate-D C s   f o r   5   d a y s .     A n d   t h e n ,   T   c e l l s   w e r e  
collected and accessed for intracellular expression of IFN-γ in CD4+ and CD8+ T cells using flow cytometry.  Original 
histograms are shown with percentage of dual-positive cells.  *p<0.05. Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
644 
 
Figure 3. Analysis of DC phenotype by flow cytometry.  Different group of DCs were harvested and processed for staining 
w i t h   a   p a n e l   o f   m A b   a s   i n d i c a t e d .    T h e   s t a i n i n g   o f   t h e   i n d i c a t e d   s u r f a c e   m a r k e r   i s   s h o w n  a n d   t he percentage of positive cells 
is stated. The MFI value are also indicated. Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
645 
 
Figure 4. Effects of HCC total RNA or lysate loading on the cytokines release of mature DCs.  Immature DCs were 
incubated with RNA (black bar) or lysate (white bar) for 3 hour and then stimulated with OK-432 (0.1 KE/ml) for 2 days.  
The supernatant were collected for TNF-α,   I L -12p70, IFN-γ, IP-10, IL-10 and TGF-β production determine by using ELISA 
m e t h o d .     T h e   s u p e r n a t a n t   c o m e   f r o m   i m m a t u r e   D C   a n d   O K -432-stimulated DC without loading any antigen are as control 
( s t r i p e   b a r ) .     Data are means ± SD of triplicates from one experiment.    *p<0.05 (RNA loading compared with lysate loading). 
 
 
Another important feature of functional DCs is 
the production of inflammatory cytokines.    Thus, the 
secretion o f   c y t o k i n e s   f r o m   D C s ,   i n c l u d i n g   I L -12p70, 
IFN-γ,  TNF-α,  IP-10,  IL-10 and TGF-β  were  further Int. J. Biol. Sci. 2010, 6 
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detected.   The  level  of  IL-12p70, IFN-γ,  TNF-α and 
IP-10 increased significantly in the culture superna-
tants  when  immature  DCs  were  stimulated  with 
OK-432 (Fig. 4).    However, OK-432 treatment did not 
induce  IL-10 and TGF-β  p r o d u c t i o n   o f   D C s .     H C C  
R N A   l o a d i n g   s l i g h t l y   d e c r e a s e d   t h e   p r o d u c t i o n   o f  
IL-1 2 p 7 0 ,   a n d   d i d   n o t   e x e r t   t h e   p r o d u c t i o n   o f   I F N -γ, 
TNF-α  and  IP-10.    However,  tumor  lysate  loading 
markedly  d e c r e a s e d   t h e   p r o d u c t i o n   o f   I L -12p70, 
IFN-γ a n d   I P -1 0 ,   m e a n w h i l e ,   i n c r e a s e d   t h e   p r o d u c t i o n  
of IL-10 especially when the Hep3b cell line is used.  
B o t h   H C C   R N A   a n d   l y s a t e   l o a d i n g   d i d   n o t   e n h a n c e  
t h e   p r o d u c t i o n   o f   T G F -β.  These results demonstrated 
that HCC lysate pulsing will impair Th1-type cyto-
kines secretion and promote anti-inflammatory cyto-
kines production of DCs. 
Effect of HCC RNA or Lysate Pulsing on the 
Stimulatory Capacity of DCs  
To  assess  the  functional  consequences  of  HCC 
tumor whole antigen-pulsed DCs, we examined the T 
cell  stimulatory  activity  of  t u m o r   R N A   o r   l y-
sate-pulsed  DCs  in  MLR  b y   C F S E   d i l u t i o n   e x p e r i-
ments.    A s   s h o w n   i n   F i g .   5 ,   b o t h   t u m o r   R N A   a n d   l y-
sate-pulsed DCs have potent stimulatory capacity.  T 
cell  proliferation  was  43.62%  (RNA  loading)  vs. 
34.23%  (lysate  loading)  for  HepG2;  34.48%  (RNA 
loading) vs. 28.9% (lysate loading) for Hep3B; 36.87% 
(RNA loading) vs. 36.20% (lysate loading) for  Huh7, 
and 39.04% (RNA loading) vs. 35.56% (lysate loading) 
for SMMC7721 respectively.    The amount of prolife-
r a t i o n   o f   T   c e l l s   w a s   c o m p a r a b l e   f o r   t w o   t y p e s   o f   a n-
tigen-loaded DCs.   
 
 
Figure 5. The stimulatory capacity of DCs pulsed with HCC total RNA or lysate. Analysis of T cells proliferation.    Au-
tologous T lymphocytes l a b e l e d   w i t h   C F S E   w e r e   m i x e d   w i t h   R N A -DCs or lysate-DCs a t   a   r a t i o   o f  1 0 : 1   ( T   c e l l s   t o   D C s )   a n d  
cocultured for 5 days.  T cell proliferation was performed using flow cytometry and the percentage of proliferated T cells is 
stated. Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
647 
 
Discussion 
Dendritic cell (DC)-b a s e d   t h e r a p y   h a s   p r o v e d   t o  
be eff e c t i v e   i n   p a t i e n t s   w i t h   a   v a r i e t y   o f   m a l i g n a n c i e s , 
including  HCC.    However,  an  optimal  preparation 
p r o t o c o l   u s i n g   D C s   a n d   t h e   b e s t   m e a n s   f o r   enhancing 
antigens has not yet been described completely.  In 
the  present  study,  we  have  demonstrated  that  DCs 
loaded with HCC total RNA are more potent antigen 
than that  loaded with lysates in activating  effctor T 
cells  s u c h   a s   T h 1   a n d   C T L   a g a i n s t   H C C   c e l l   l i n e s ,  
which was evidenced by a higher percentage of tumor 
cell killing, as well as higher IFN-γ secretion of CD4+ 
and CD8+ T cells in DCs loaded with HCC total RNA.  
A s   w e l l   k n o w n ,   a ctivation and polarization of naive T 
cells  requires t h r e e   s i g n a l s   f r o m   D C .     Signal  1is  the 
interaction between major histocompatibility complex 
(MHC)  molecules  containing  peptide  fragments  on 
the  DC and the  T-c e l l   r e c e p t o r   ( T C R )   o n   t h e   T   c e l l .    
Signal 2 is the interaction between costimulatory mo-
l e c u l e s   ( e . g .   C D 8 0 / 8 6 )   o n   t h e   s u r f a c e   o f   t h e   D C   w i t h  
l i g a n d s   ( e . g .   C D 2 8 )   o n   t h e   T -cell surface.    Signal 3 is 
the  secretion  of  proinflammatory  cytokines  (e.g.  in-
terleukin 12 (IL-12)) b y   t h e   D C  (26-28).    Signal  1  and 
signal 2 allow naive T cells to develop into protective 
effector  cells,   w h i l e   s i g n a l   3   p r o m o t e s   t h e   a c t i v a t e d  
CD4+ and CD8+ to differentiate  into  Th1  and  CTL 
(29-3 1 ) .     I n   o u r   s t u d y ,   w e   f o u n d   t h a t   l o a d i n g   D C   w i t h  
H C C   t o t a l   R N A   a n d   l y s a t e   d i d   n o t   r e s u l t   i n   t h e   d e-
c r e a s e d   e x p r e s s i o n   o f   M H C   c l a s s   I I   a n d   costimulatory 
molecules, indicating that the two type of antigen did 
n o t   i m p a i r   t h e   s i g n a l   1   a n d  signal 2.  However, unlike 
RNA,  HCC  lysate  pulsing  significantly  suppressed 
the inflammatory cytokines such  as  IL-12 and IFN-γ 
p r o d u c t i o n ,   i n d i c a t i n g   t h a t   H C C   l y s a t e   w o u l d   d i s-
o r d e r   s i g n a l   3 .     T h u s ,   l o a d i n g   D C   w i t h   H C C   l y s a t e  
induced  limited  T  cells  respons e s   m i g h t   b e   d u e   t o  
decreased inflammatory cytokines environment.  
The cytokine microenvironment plays a key role 
i n   T   h e l p e r   c e l l   d i f f e r e n t i a t i o n   t o w a r d   T h1   o r   T h2 cell 
type during immune responses (32).    The IL-12 pro-
d u c e d   b y   D C   p o l a r i z e s  the T-cell response towards a 
Th1 phenotype, which is believed to be preferential 
for cancer immunotherapy (33,  34).    The absence of 
IL-12p70 leads to depressed Th1-responses and hence 
a paucity of IFN-γ-support for CD8+ CTL.  It has been 
reported that tumor lysate, such as melanoma, would 
suppress  IL-12p70  secretion,  resulting  in  less  effi-
ciently generating Th1-responses from naïve T-cells, 
and  restoring IL-12p70 production  of DC permitted 
effective generation of Th1-responses (14-16).    These 
results are in agreement with our studies.     T h u s ,  tu-
mor RNA loading may be a better choice to  induce 
Th1 and CTL response compared with tumor lysate.   
IL-12  production  is  positively  regulated  by 
IFN-γ, which  IL-12  itself  induces (35,  36).    Multiple 
studies have shown that DCs also produce IFN-γ (37, 
38), s u g g e s t i n g   t h e   p r e s e n c e   o f   a n   a u t o c r i n e -positive 
feedback pathway between IL-12 and IFN-γ for  DC 
activation (39).    I n   o u r   s t u d y ,   w e   f o u n d   O K -432 sti-
mulation could also promote human DCs to secrete 
high level of IFN-γ, and HCC lysate loading signifi-
cantly  suppress  IFN-γ  production  as  well  as  IL-12, 
indicating  HCC  lysate  could  destroy  the  positive 
f e e d b a c k   l o o p   o f   I L -12 and IFN-γ, and then influence 
the Th1 response induction.   
In summary, our data showed that pulsing  DCs 
with  total  RNA  as  a n t i g e n   s e e m s   t o   b e   a   p r o m i s i n g  
alternative to lysate for priming better Th1 and CTL 
r e s p o n s e   a g a i n s t   h e p a t o m a   c e l l s .     O u r   s t u d y   m i g h t  
provide  a  reasonable  strategy  for  DC-based  immu-
notherapy in HCC.  Further investigation should  be 
done to evaluate the efficacy of this strategy in clinical 
application. 
Acknowledgements 
T h i s   w o r k   w a s   s u p p o r t e d   b y   t h e   N a t i o n a l   N a t-
ural  Science  Foundation  of  China  (30571717, 
u0772002, 30700985).  We thank Dr. Hong-w e i   L i u   f o r  
critical reading of this manuscript. 
Conflict of Interest 
T h e   a u t h o r s   d e c l a r e   t h a t   t h e y   d o   n o t   h a v e   any 
conflict of interest with respect to this manuscript. 
References 
1.  Okuda  K.  Hepatocellular  carcinoma.  J  Hepatol  2000;  32  (1 
Suppl): 225-237. 
2.  Parkin DM,  Bray F, Ferlay  J, Pisani  P. Estimating  the  world 
cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156. 
3.  Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for 
progress. J Clin Oncol 2005; 23: 2892-2899. 
4.  Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by 
inducing immunity via dendritic cells. Immunol Rev 2007; 220: 
129-150. 
5.  Banchereau J, Palucka AK. Dendritic cells as therapeutic vac-
cines against cancer. Nat Rev Immunol 2005; 5: 296-306 
6.  Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, 
Labarrière N, et al. Immunologic and clinical effects of injecting 
mature  peptide-loaded dendritic cells by intralymphatic and 
intranodal routes in metastatic melanoma patients. Clin Cancer 
Res. 2006; 12: 7380-7388. 
7.  Wierecky J, Müller MR, Wirths S, Halder-Oehler E, Dörfel D, 
Schmidt  SM,  et  al.  Immunologic and clinical responses after 
vaccinations with peptide-pulsed dendritic cells in metastatic 
renal cancer patients. Cancer Res. 2006; 66: 5910-5918. 
8.  Lee WC, Wang HC, Jeng LB, Chiang YJ, Lia CR, Huang PF, et 
al. Effective treatment of small murine hepatocellular carcino-
ma by dendritic cells. Hepatology 2001; 34: 896-905. Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
648 
9.  Wang XH, Qin Y, Hu MH, Xie Y. Dendritic cells pulsed with 
gp96-peptide  complexes  derived  from  human  hepatocellular 
carcinoma  (HCC)  induce  specific  cytotoxic  T  lymphocytes. 
Cancer Immunol Immunother 2005; 54: 971-980. 
10.  I w a s h i t a   Y ,   T a h a r a   K ,   G o t o   S ,   S a s a k i   A ,   K a i   S ,   S e i k e   M ,   et al. A 
phase I study of autologous dendritic cell-based  immunothe-
rapy for patients with unresectable primary liver cancer. Cancer 
Immunol Immunother 2003; 52: 155–161. 
11.  Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. 
Vaccination  of  advanced  hepatocellular  carcinoma  patients 
with  tumor lysate-pulsed dendritic cells: a clinical trial. J Im-
munother 2005; 28: 496-504. 
12.  Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, 
et al. A   p h a s e   I I   s t u d y   o f   a d o p t i v e   i m m u n o t h e r a p y   u s i n g   d e n-
d r i t i c   c e l l s   p u l s e d   w i t h   t u m o r   l y s a t e   i n   p a t i e n t s   w i t h   h e p a t o-
cellular carcinoma. Hepatology 2009; 49:124-132. 
13.  Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell 
immunotherapy: mapping the way. Nat Med 2004; 10: 475-480. 
14.  Jackson AM, Mulcahy LA, Zhu XW, O'Donnell D, Patel PM. 
Tumour-mediated disruption of dendritic cell function: inhi-
biting the MEK1/2-p44/42 axis restores IL-12 production and 
Th1-generation. Int J Cancer 2008; 123: 623-632. 
15.  Y a n g   D H ,   P a r k   J S ,   J i n   C J ,   K a n g   H K ,   N a m   J H ,   R h e e   J H ,   e t   a l . The 
dysfunction and abnormal signaling pathway of dendritic cells 
l o a d e d   b y   t u m o r   a n t i g e n   c a n   b e   o v e r c o m e   b y   n e u t r a l i z i n g  
VEGF in multiple myeloma. Leuk Res 2009; 33: 665-670. 
16.  Hatfield P, Merrick AE, West E, O'Donnell D, Selby P, Vile R, et 
al. Optimization of Dendritic Cell Loading  With Tumor  Cell 
Lysates  for  Cancer.  Immunotherapy.  J Immunother 2008;  31: 
620-632. 
17.  Gilboa E.  DC-based  cancer  vaccines.  J Clin Invest 2007;  117: 
1195-1203. 
18.  Tyagi RK, Mangal S, Garg N, Sharma PK. RNA-based immu-
n o t h e r a p y   o f   c a n c e r :   r o l e   a n d   t h e r a p e u t i c   i m p l i c a t i o n s   o f   d e n-
dritic cells. Expert Rev Anticancer Ther 2009; 9: 97-114. 
19.  Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with 
tumour-mRNA  transfected  dendritic  cells.  Cancer  Immunol 
Immunother 2006; 55: 1432-1442. 
20.  G r ü n e b a c h   F ,   M ü l l e r   M R ,   B r o s s a r t   P .   N e w   d e v e l o p m e n t s   i n  
dendritic cell-based vaccinations: RNA translated into clinics. 
Cancer Immunol Immunother 2005; 54: 517-525. 
21.  Gilboa  E,  Vieweg   J .   C a n c e r   i m m u n o t h e r a p y   w i t h  
mRNA-transfected  dendritic  cells.  Immunol  Rev  2004;  199: 
251-263. 
22.  N a i r   S ,   B o c z k o w s k i   D .   R N A -transfected dendritic cells. Expert 
Rev Vaccines 2002; 1: 507-513. 
23.  Mitchell DA, Nair SK. RNA transfected dendritic cells as cancer 
vaccines. Curr Opin Mol Ther 2000; 2: 176-181.  
24.  Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer 
immunotherapy. J Clin Invest 2000; 106:1065-1069. 
25.  S c h n u r r   M ,   G a l a m b o s   P ,   S c h o l z   C ,   T h e n   F ,   D a u e r   M ,   E n d r e s   S ,  
et al. Tumor cell lysate-pulsed human dendritic cells induce a 
T-cell response against pancreatic carcinoma cells: an in vitro 
m o d e l   f o r   t h e   a s s e s s m e n t   o f   t u m o r   v a c c i n e s .  Cancer Res 2001; 
61: 6445-6450. 
26.  C l a r k   R ,   K u p p e r   T .   Old  meets  new:  the  interaction  between 
innate and adaptive immunity. J Invest Dermatol 2005;  125: 
629-637. 
27.  R e i s   e   S o u s a   C .   Dendritic  cells  in  a  mature  age.  Nat  Rev 
Immunol 2006; 6: 476-483. 
28.  Kapsenberg  ML.  Dendritic-cell  control  of  pathogen-driven 
T-cell polarization. Nat Rev Immunol 2003; 3: 984-993. 
29.  Baxter  AG,  Hodgkin  PD.  Activation  rules:  The  two-signal 
theories  of  immune  activation.  Nat  Rev  Immunol  2002; 
2:439–446. 
30.  C u r t s i n g e r   J M ,   S c h m i d t   C S ,   M o n d i n o   A ,   L i n s   D C ,   K e d l   R M ,  
Jenkins MK, et al. Inflammatory cytokines provide a third sig-
nal for activation of naive CD4+ and CD8+ T cells. J Immunol. 
1999; 162: 3256–3262. 
31.  Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell 
priming  by  type-1  and  type-2  polarized  dendritic  cells:  the 
concept of a third signal. Immunol Today 1999; 20: 561–567. 
32.  Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunologi-
cal decision-making: how does the immune system decide to 
mount  a  helper  T-cell  response?  Immunology  2008;  123: 
326-338. 
33.  Giorgio Trinchieri. Interleukin-12 and the regulation of innate 
resistance and adaptive immunity. Nature Reviews Immunol-
ogy 2003; 3: 133-146. 
34.  Langrish  CL,  McKenzie  BS,  Wilson  NJ,  de  Waal  Malefyt  R, 
K a s t e l e i n   R A ,   C u a   D J .   I L -12 and IL-23: master regulators of in-
nate and adaptive immunity. Immunol Rev 2004; 202: 96–105. 
35.  Ma X, Chow JM, Gri G, Carra G, Gerosa F, Wolf SF, et al. The 
interleukin-1 2   p 4 0   g e n e   p r o m o t e r   i s   p r i m e d   b y  interferon-γ in 
monocytic cells. J Exp Med 1996;183: 147–157. 
36.  Y o s h i d a   A ,   K o i d e   Y ,   U c h i j i m a   M ,   Y o s h i d a   T O .   I F N -γ induces 
IL-1 2   m R N A   e x p r e s s i o n   b y   a  murine macrophage cell line, J774. 
Biochem Biophys Res Commun 1994;198: 857–861. 
37.  O h t e k i   T ,   F u k a o   T ,   S u z u e   K ,   M a k i   C ,   I t o   M ,   N a k a m u r a   M ,  et al.  
Interleukin-12-dependent  i n t e r f e r o n   γ   p r o d u c t i o n   b y   C D 8 α +  
lymphoid dendritic cells. J Exp Med 1999; 189: 1981–1986. 
38.  P u l e n d r a n   B ,   L i n g a p p a   J ,   K e n n e d y   M K ,   S m i t h   J ,   T e e p e   M ,  
Rudensky A, et al. Developmental pathways of dendritic cells 
in vivo: distinct function, phenotype, and localization of den-
dritic cell subsets in FLT3 ligand- treated mice. J Immunol 1997; 
159: 2222-2231. 
39.  Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu 
S. IFN-γ   p r o d u c t i o n   b y   a n t i g e n -presenting  cells:  mechanisms 
emerge. Trends Immunol 2001; 22: 556-560. 